Skip to content
You are now leaving https://www.ionispharma.com to visit

The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy

SPINRAZA, the first and only approved treatment for spinal muscular atrophy (SMA), is supported by the largest well-controlled SMA clinical development program conducted to date The majority of infants treated with SPINRAZA in the ENDEAR study achieved motor milestones compared to untreated infants